



## Brown University Health - Institutional Biosafety Committee Minutes

March 2, 2026 Videoconference

Present: Dr. Jayasuriya, (Chairperson), Dr. Dubielecka-Szczerba (Vice Chairperson), Mr. Carrera (alternate for Mr. McEvoy), Mr. Dooner, Dr. Gregory, Dr. Helwig, Dr. Li (Associate Chair), and Mr. O'Reilly

Absent: Ms. Brilliant, Dr. Jackson, Mr. McEvoy, and Dr. Mehta,

Investigators Submitting Applications for Review: Dr. Jayasuriya

Support Staff: Ms. Poore

---

Note: Unless otherwise stated all motions were unanimously approved for 3 years.

After determining that quorum was met, Dr. Jayasuriya convened the meeting at 12:03 p.m.

The following voting members were present when the meeting began: Dr. Jayasuriya, Dr. Dubielecka-Szczerba, Mr. Carrera, Mr. Dooner, Dr. Gregory, Dr. Helwig, Dr. Li, and Mr. O'Reilly

**Welcome and Opening Remarks:** The IBC chair read the COI statement aloud to remind members it is their responsibility to identify if they have a conflict of interest and to recuse themselves from review of that item.

### 1 **Review of Previous Minutes from 2/2/2026**

Committee Action: The minutes were approved as submitted.

Vote: Number of members present 8, Approved 8, Opposed 0, Abstained 0 Recused 0

### 2 **New Studies DNA**

Note: Dr. Dubielecka-Szczerba assumed responsibilities of the Chair.

#### 2.1 **[2416621-1] Viral Particle Generation for Functional Gene Knockdown Studies in Meniscal Cells**

**PI:** Chathuraka Jayasuriya, PhD

**Reference Number:** 5001-26

**Sponsor:** Orthopedics

**Submission Type:** New Project

**Review Type:** Full Committee Review

Primary Reviewer: Jisu Li, Stephen Gregory

Discussion:

- Dr. Jayasuriya provided an overview of the project. This study will include the use of lentiviral constructs targeting three genes. The constructs will be purchased and replication-incompetent lentiviral particles will be produced in-house.
- Dr. Jayasuriya provided a detailed description of the replication competence testing that will be performed after viral particles are generated.
- Dr. Jayasuriya explained that the cells were previously obtained from human patients with IRB approval and immortalized in his lab.

Requested corrections:

- Rec DNA Application, pg. 1, include interoffice mailing address
- Item 3, include TurboGFP and correct typo with IL-1RN
- Item 4a, please split out the expressed genes and include the backbone and helpers

- Item 4a, include the building and room for the -80 freezer
- Item 6, add shRNA targeting TurboGTP control
- Item 10, correct typo in work site
- Viral Safety Info sheet, under the second question describing how the virus has been modified, please replace “gene of interest” with the three genes

The IBC reviewed this project with regard to: potential virulence, pathogenicity or environmental stability of the agent; the types of manipulations planned; the source and nature of the inserted DNA sequences; and the host and vectors to be used. IBC assessment is as follows:

Recombinant DNA materials will be used in humans	Yes	X No
Recombinant DNA materials will be used in animals.	Yes	X No
Training and Expertise of personnel is adequate.	X Yes	No
Facilities, procedures and practices are adequate.	X Yes	No
Annual testing for replication competence is necessary.	X Yes	X No
Biohazard containment level _____ BL2 _____		
Applicable Section of the NIH Guidelines: _____ III-D _____		

Committee Action: The committee voted to require modifications to secure approval. Dr. Dubielecka will serve as the designated reviewer for the requested corrections.

Vote: Number of members present 7, Approved 7 Opposed 0 Abstained 0, Recused 1  
 NOTE: Dr. Jayasuriya recused for COI, the quorum was maintained.

**3. Discussion item: Discussion item: Animal containment following treatment with human source cells**

- Dr. Trivedi has approval IACUC (#5007-25) and IBC (#5023-17) to inject Sprague Dawley rats with genetically modified human cells. The researchers have asked whether to house the rats under ABSL-1 or ABSL-2, as the IBC application does not address animal containment.
- The current IBC expedited review application references the use of human source cells in immunocompromised mice and does not refer to immune competent animals, or other species.
- Dr. Helwig noted that Brown University houses animals under ABSL-2 for the life of the animal following treatment with human source cells.
- The members agreed that the BUH IBC policy and practice should align with Brown University, as the Brown IACUC is now responsible for oversight of animal use at BUH.
- Ms. Poore will provide updated IBC forms for review at the April meeting.

**4. Continuing Reviews DNA**

**5. Revisions- Full Board DNA**

**6. Administrative Check-In**

**7. Expedited and Revision Reviews DNA**

a. **[2237805-7] IBC Committee: LS-P-MuSIC (BO45230): A Randomized Phase II, Double-Blind, Multicenter Study Evaluating The Efficacy And Safety Of Autogene Cevumeran Plus Nivolumab Versus Nivolumab As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma**

**PI:** Galina Lagos, MD  
**Reference Number:** 503024  
**Sponsor:** F. Hoffmann-La Roche Ltd  
**Submission Type:** Revision

**Review Type:** Expedited Review  
**Action:** Approved  
**Effective Date:** February 19, 2026  
**Project Status:** Active  
**Project Expiration:** October 6, 2027  
**Next Report Due:** October 1, 2026  
**Remarks:** protocol amendment v. 4

b. **[1480956-67] COBREII Lentivirus Construct Core PI:**

Olin Liang, Ph.D.

**Reference Number:** 504619, lentivirus, retrovirus  
**Sponsor:** Federal  
**Submission Type:** Amendment/Modification

**Review Type:** Expedited Review  
**Action:** Modifications Required  
**Effective Date:** February 19, 2026  
**Project Status:** Active  
**Project Expiration:** July 31, 2026  
**Remarks:** Add Coro West 5.05 Tissue Culture room as an alternate performance site, as CW 4.200 was recently flooded.

c. **[2028162-8] Conditionally Replicative Oncolytic Adenovirus PI:**

Olin Liang, Ph.D.

**Reference Number:** 502223 adenovirus  
**Sponsor:** Brown Physicians Inc.  
**Submission Type:** Amendment/Modification

**Review Type:** Expedited Review  
**Action:** Modifications Required  
**Effective Date:** February 19, 2026  
**Project Status:** Active  
**Project Expiration:** April 2, 2026  
**Next Report Due:** February 14, 2026

**Remarks:** Add Coro West 5.05 Tissue Culture room as an alternate performance site, as CW 4.200 was recently flooded.

**d. [2028162-9] Conditionally Replicative Oncolytic Adenovirus**

**PI:** Olin Liang, Ph.D.  
**Reference Number:** 502223 adenovirus  
**Sponsor:** Brown Physicians Inc.  
**Submission Type:** Response/Follow-Up  
  
**Review Type:** Expedited Review  
**Remarks:** corrections from pkg 8

**8. Administrative Reviews DNA**

**a. [2261837-4] IBC Committee: LS-P-IGNYTE-3: A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]**

**PI:** Maria Constantinou, MD  
**Reference Number:** 501325 ceded to WCG  
**Sponsor:** Replimune, Inc.  
**Submission Type:** Amendment/Modification  
  
**Review Type:** Administrative Review  
**Action:** Acknowledged  
**Effective Date:** January 27, 2026  
**Project Status:** Active  
**Project Expiration:** March 14, 2028  
**Next Report Due:** April 1, 2026  
**Remarks:** protocol amendment v2, IBC review ceded to WCG

**9. Exempt DNA**

**10. Other Business DNA**

**11. End of DNA Business**

**12. Start of Hazard Business**

**13. New Studies Hazard**

**14. Expedited and Revision Reviews Hazard**

**15. Administrative Reviews Hazard**

**16. Other Business Hazard**

**The meeting adjourned at 12:36 p.m.**